Kintara Therapeutics Files 8-K with Shareholder Vote and Financial Updates

TL;DR

KINTARA filed an 8-K on 9/20/24 covering shareholder votes, Reg FD, and financials. Former names DelMar and Berry Only noted.

AI Summary

Kintara Therapeutics, Inc. filed an 8-K on September 20, 2024, reporting on the submission of matters to a vote of security holders, Regulation FD disclosures, and financial statements. The filing also notes the company's former names, DelMar Pharmaceuticals, Inc. and Berry Only Inc., and its incorporation in Nevada.

Why It Matters

This 8-K filing provides crucial updates on corporate governance and financial reporting, which are important for investors to assess the company's current status and future direction.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse events.

Key Numbers

• 001-37823 — SEC File Number (Identifies the company's filing history with the SEC.)
• 99-0360497 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Kintara Therapeutics, Inc. (company) — Registrant
• DelMar Pharmaceuticals, Inc. (company) — Former company name
• Berry Only Inc. (company) — Former company name
• Nevada (jurisdiction) — State of incorporation

FAQ

Filing Documents

• ktra-20240920.htm (8-K) — 76KB
• ktra-ex99_1.htm (EX-99.1) — 30KB
• img40499469_0.jpg (GRAPHIC) — 19KB
• 0000950170-24-108415.txt ( ) — 263KB
• ktra-20240920.xsd (EX-101.SCH) — 27KB
• ktra-20240920_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On September 20, 2024, Kintara Therapeutics, Inc. ( " Kintara ") convened and then adjourned its 2024 Special Meeting of Stockholders (the " Special Meeting ") being held to consider and vote on the following proposals: (a) the proposal to approve the issuance of shares of common stock of Kintara (the " Common Stock ") issuable in connection with the Agreement and Plan of Merger, dated as of April 2, 2024 (the " Merger Agreement "), by and among Kintara, TuHURA Biosciences, Inc. (" TuHURA ") and Kayak Mergeco, Inc. (" Merger Sub "); (b) the proposal to approve, pursuant to Nevada Revised Statutes 78.2055, a reverse stock split of only the outstanding shares of Kintara's Common Stock and other outstanding securities of Kintara (with no change to the authorized capital stock of Kintara) at a ratio ranging from 1-for-20 to 1-for-40, with such ratio to be determined in the discretion of Kintara's board of directors and with such reverse stock split to be effected at such time and date as determined by Kintara's board of directors in its sole discretion; (c) the proposal to approve an increase in the number of authorized shares of Kintara's Common Stock to 400,000,000, to be effected at such time and date as determined by Kintara's board of directors in its sole discretion (the " Charter Proposal "); (d) the proposal to approve the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan, which was approved by Kintara's board of directors on August 7, 2024 subject to stockholder approval at the Special Meeting and upon consummation of the merger of Merger Sub with and into TuHURA (the " Merger "), with TuHURA surviving the Merger as a wholly-owned subsidiary of Kintara; (e) the proposal to approve a change the state of incorporation of Kintara from the State of Nevada to the State of Delaware (the " Reincorporation ") and the plan of conversion attached to the proxy statement/prospectus as Annex D including the

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 20, 2024, Kintara Therapeutics, Inc. (" Kintara ") issued a press release announcing the adjournment of the Special Meeting to 9:00 a.m., Eastern Time, on October 4, 2024 to allow additional time for stockholders to vote on the Kintara Proposals. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission (the " SEC "), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing. Additional Information about the Proposed Merger and Where to Find It This Current Report on Form 8-K does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This Current Report on Form 8-K relates to the proposed Merger of Kintara and TuHURA. In connection with the proposed Merger, Kintara has filed a Registration Statement on Form S-4 and a definitive proxy statement and a final prospectus of Kintara (the "proxy statement/prospectus"). This registration statement was declared effective on August 13, 2024 and Kintara has filed or may file other documents regarding the proposed Merger with the SEC. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE DEFINITIVE PROXY STATEMENT/PROSPEC

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K and the communication attached hereto as Exhibit 99.1 contain forward-looking statements based upon Kintara's and TuHURA's current expectations. This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. These statements are only predictions. Kintara and TuHURA have based these forward-looking statements largely on their then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond each of Kintara's and TuHURA's control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the risk that the conditions to the closing or consummation of the proposed Merger are not satisfied, including the failure to obtain Kintara stockholder approval for the proposed Merger; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Kintara and TuHURA to consummate the transactions contemplated by the proposed Merger; (iii) risks related to Kintara's and TuHURA's ability to correctly estimate their respective operating expenses and expenses associated with the proposed Merger, as applicable, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the resulting combined company upon closing and other events and unanticipated spending and costs that cou

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release of Kintara Therapeutics, Inc. issued September 20, 2024.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINTARA THERAPEUTICS, INC. Date: September 20, 2024 By: /s/ Robert E. Hoffman Name: Robert E. Hoffman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR